A 52-year-old man with a history of chronic alcohol use presents with a 2-week history of fever, dyspnea, and bleeding gums. Laboratory findings: Hb 6.8 g/dL, WBC 1800/μL (with 85% blasts), platelets 28,000/μL. Peripheral blood smear shows numerous abnormal blasts with Auer rods. Bone marrow aspiration confirms acute myeloid leukemia (AML). The patient is hemodynamically stable with no signs of disseminated intravascular coagulation (DIC). What is the most appropriate immediate next step?

Explanation

## Clinical Context This patient has newly diagnosed AML with high blast burden (85% blasts), presenting with constitutional symptoms and cytopenias. Before initiating chemotherapy, the critical immediate concern is **tumor lysis syndrome (TLS)** prevention — not yet active DIC, CNS prophylaxis, or transfusion targets. ## Tumor Lysis Syndrome Risk in AML ```mermaid flowchart TD A[Newly diagnosed AML with high blast burden]:::outcome --> B{Risk of TLS?}:::decision B -->|Yes - HIGH| C[Aggressive hydration + Allopurinol/Febuxostat]:::action B -->|Monitor| D[Uric acid, LDH, K+, PO4, Creatinine]:::action C --> E[Prevent hyperuricemia & hyperkalemia]:::outcome E --> F[Then proceed to induction chemotherapy]:::action D --> G{TLS develops?}:::decision G -->|Yes| H[Rasburicase if available]:::urgent G -->|No| I[Continue monitoring & chemotherapy]:::action ``` ## Why Pre-Chemotherapy TLS Prevention is Critical **Key Point:** Tumor lysis syndrome occurs when rapidly dividing malignant cells die, releasing intracellular contents (potassium, phosphate, uric acid, nucleic acids). In AML with >80% blasts, chemotherapy-induced cell death can trigger life-threatening hyperkalemia, hyperphosphatemia, hyperuricemia, and acute kidney injury within hours. **High-Yield:** The sequence in AML management is: 1. **Prevent TLS** (hydration + urate-lowering agents) — BEFORE chemotherapy 2. Assess CNS involvement (if indicated by symptoms/high-risk features) 3. Initiate induction chemotherapy 4. Transfuse judiciously (avoid over-transfusion which increases viscosity and TLS risk) **Warning:** Starting chemotherapy in a high-blast AML without TLS prophylaxis is dangerous. Rapid cell death can cause fatal hyperkalemia or acute renal failure within 24–48 hours. ## Management Priorities in Newly Diagnosed AML | Step | Timing | Rationale | |------|--------|----------| | Hydration + Allopurinol/Rasburicase | **BEFORE chemotherapy** | Prevent hyperuricemia, hyperkalemia, acute kidney injury | | Baseline labs (uric acid, LDH, K+, Cr, PO4) | **IMMEDIATELY** | Establish baseline for TLS monitoring | | Assess CNS involvement | Before induction (if high-risk) | Prophylaxis or treatment planning | | Induction chemotherapy | After TLS prophylaxis established | Standard 7+3 regimen (cytarabine + daunorubicin) | | Transfusion strategy | Restrictive (Hb >7, Plt >20–30) | Avoid over-transfusion; reduce viscosity | **Mnemonic: TLS Prevention in AML — HAUL** - **H**ydration (aggressive IV fluids, target urine output 200–300 mL/hr) - **A**lopurinol or **R**asburicase (urate-lowering agents) - **U**ric acid & **L**DH monitoring (baseline + serial) - **L**aboratory monitoring (K+, PO4, Cr, uric acid) **Clinical Pearl:** Rasburicase (recombinant uricase) is preferred over allopurinol in high-risk TLS because it directly converts uric acid to allantoin (more soluble). Allopurinol prevents new uric acid formation but does not clear existing uric acid. [cite:Harrison 21e Ch 110; NCCN AML Guidelines 2023]